Biome Australia (ASX:BIO) said it received positive results of the core functional characterization studies conducted by the cell culture lab of one of its research partners, according to a Thursday Australian bourse filing.
The in vitro studies investigated the functional characteristics of Biome's Lactobacillus plantarum probiotic strain BMB18 using two types of cell cultures.
Caco-2 epithelial cell culture studies model the intestinal epithelial barrier and were used to study the ability of the strain to repair and prevent intestinal tissue damage.
Transepithelial peripheral blood mononuclear cell culture study was used to stimulate immune responses.
The strain exhibited an ability to "effectively modulate immune responses and inflammation, reduce oxidative stress, and maintain intestinal barrier integrity," per the filing.
The firm's shares fell a little over 3% on market close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.